A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Carisbamate (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; SK Life Science
- 15 Jun 2012 Drug company SK Life Science added to the associations field as reported by ClinicalTrials.gov record.
- 29 Jan 2009 Actual patient numbers (132) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.